SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Stefan Schreiber  ¹     Geert R. D'Haens  ²     Fraser Cummings  ³     Peter Irving  ⁴     Byong Duk Ye  ⁵     Yoorim An  ⁶     Dong-Hyeon Kim     Sangwook Yoon     Shomron Ben-Horin  ⁷     Walter Reinisch  ^8    
1 University Hospital Schleswig-Holstein, Kiel, Germany
² Amsterdam University Medical Centers, Amsterdam, Netherlands
³ University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
⁴ Guy’s and St Thomas’ Hospital, London, United Kingdom
⁵ University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of
⁶ Celltrion Healthcare, Incheon, Korea, Republic of
⁷ Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
⁸ Medical University of Vienna, Vienna, Austria

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)